Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.

Alexander Drilon, MD, discusses future directions for zidesamtinib in TKI-naive, ROS1-positive NSCLC following the ARROS-1 trial.

Alexander Drilon, MD, discusses phase 1/2 ARROS-1 efficacy and safety findings with zidesamtinib in TKI-naive, ROS1-positive NSCLC.

Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.

JBS-003 will be evaluated in an ongoing phase 3 trial designed to determine whether investigators can identify patients who can safely receive less radiation.

Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.

Michael J. Morris, MD, discusses key ongoing clinical trials in prostate cancer.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.

Michael J. Morris, MD, discusses updated data from the phase 3 PSMAddition trial supporting lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA-positive mHSPC.

Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.

Michael J. Morris, MD, discusses phase 3 PSMAddition trial data supporting lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA-positive mHSPC.

Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.

Michael J. Morris, MD, discusses the significance of the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.

Hamza Hashmi, MD, outlines considerations for identifying patients with early relapsed/refractory multiple myeloma as candidates for CAR T-cell therapy.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Lorenzo Falchi, MD, discusses key unmet needs and important next steps for diffuse large B-cell lymphoma research.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Alan L. Ho, MD, PhD, discusses an upcoming phase 3 trial evaluating Oz-V in OPSCC and key aspects of its design.

Christian Grommes, MD, discusses how BTK inhibitors and CAR T-cell therapy fit into the relapsed/refractory primary CNS lymphoma treatment paradigm.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

Michael A. Postow, MD, discusses the current evidence gaps surrounding the management of irAEs in melanoma in the long term.

Michael A. Postow, MD, discusses the importance of multidisciplinary coordination following immune checkpoint inhibitor therapy completion for patients with melanoma.

Michael A. Postow, MD, discusses the significance of understanding how to identify late-onset irAEs and underlying comorbidities unrelated to treatment in melanoma.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

Experts highlight some top hematologic oncology data presented at ASCO 2026, including from key studies in multiple myeloma and diffuse large B-cell lymphoma.

Geoffrey Ku, MD, discusses data from HERIZON-GEA-01 showing zanidatamab plus tislelizumab benefits patients with HER2-positive GEA regardless of PD-L1 status.

The FDA has approved orally disintegrating nilotinib tablets for select patients with chronic myeloid leukemia.

Alan L. Ho, MD, PhD, discusses next steps for the evaluation of Oz-V in OPSCC based on its phase 2 efficacy in patients with treatment-refractory disease.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.